06.27.25 -- ADCs Unleashed: Navigating Development Hurdles In Targeted Cancer Therapy

Since life science professionals hail from diverse backgrounds, educations, and work experiences, different mentorship models serve their varied development needs and learning styles.

Innovations in drug delivery formats are enabling more patient-centric treatments and helping to boost patient compliance. Learn about the advances being developed to expand ODT technology.

How is the pharmaceutical industry increasing aseptic processing safety? An ISPE event showcased innovations like robotics and improved risk management, aligning with recent regulatory guidance.

IQ, OQ, and PQ validations ensure equipment reliability, compliance, and quality in medical device and pharmaceutical manufacturing, meeting regulatory standards.

Explore the most recent rewrite of the EU Annex 1 document as well as the contamination control strategy outlined within.

Clinical bridging studies demonstrate bioequivalence or bioavailability for drug-device combinations, using pharmacokinetic parameters and a risk-based, four-step approach.

To leverage the benefits of peptide therapeutics, identify an experienced chemical material manufacturer that can produce unique peptide building blocks with quality, efficiency, and continuous compliance.

Maintaining a contamination-free environment is crucial in drug compounding. Learn how isolator systems can improve safety, efficiency, and regulatory compliance.

Quality management in healthcare and life sciences is crucial for optimizing patient health. Find out how modern quality management systems optimize patient outcomes and enhance safety.

Here, we characterize the new production directions in pharmacy and describe the flexible equipment to improve pharma efficiency, purity, and production safety in the coming decade.

Read how validated preclinical models of incision-induced pain can accelerate the development of effective therapies for postoperative pain by closely mimicking human pain responses.

See how PBPK models combined with custom and off-the-shelf in vitro tools and solubility enhancement expertise can reduce the need for drug product reformulation or repeated preclinical or clinical studies.

Executive Director of Pharmaceutical Sciences Srinivasan Shanmugam, Ph.D., discusses pediatric patient compliance, regulations impacting trial access, excipients within formulations, and more.

Medicines for infants and children face unique formulation challenges. Gain insight into key considerations, including developmental physiology, age specifics, precise dosing, and more